Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as  BTG2, SMARCA4, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 30/January/2019, `7.38 pm

Molecular therapy for Autoimmune diabetes: AIRE (Autoimmune regulator) increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 30/January/2019, 7.26 pm
January 30, 2019
 Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Elafibranor (GFT505), an experimental drug for diabetes, insulin resistance, dyslipidemia, nonalcoholic steatohepatitis (NASH), increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 31/January/2018, 6.00 am
January 31, 2019
Show all

What we say:

Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports here that: Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as  BTG2, SMARCA4, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene


The Significance of the study to Public health relevance:

First, given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die due to lack of curative treatment available at present; (ii) cancer deaths globally are expected to be doubled by 2030;  and (iii) cancer causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a way to prevent an individual from being susceptible to cancer by strengthening his/her own immune system (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (iii) a side-effect-free natural product-based anticancer drugs that target cancer stem cells; and (iv) a way to effectively treat and prevent metastatic progression and relapse of ovarian cancers.

Second, given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant p53-overexpressing tumors; (4) cancer causes the highest economic loss compared to all the known causes of death worldwide; and (5) cancer causes the considerable economic loss worldwide, there is an urgent need to find a way to effectively treat and stall metastatic progression and relapse of mutant p53-overexpressing human cancers.


From research findings to therapeutic opportunity :

(i) Therapeutic strategy:

This study suggests a therapeutic strategy for stalling the progression of p53-deficient/deleted or mutant-p53 expressing metastatic cancers. By activating tumor suppressor p53’s unmutated “homologous protein such as TAp73/p63” in p53-deficient or mutant-p53 expressing metastatic cancer cells, one can stall their progression.

(ii) Research findings: Clostridium butyricum MIYAIRI 588 (CBM588), a Histone deacetylase (HDAC) inhibitor, has been shown to inhibit cancer progression. However, the mechanism of action remains largely unknown. This study suggests, for the first time, that Clostridium butyricum MIYAIRI 588 (CBM588), by increasing the expression of its target genes, it may: (i) decrease the expression of a number of oncogenes and DNA repair proteins; (ii) increase the expression of tumor/metastasis suppressor genes, such as  BTG2 and SMARCA4,; (iii) increase the expression of a number of other tumor suppressor genes, including p53/TA-p73/p63, and their target genes, INKa/p19ARF and others (Figure 1);(iv) activate tumor/metastasis suppressor network; (v) inhibit immunosuppressive/immune-inhibitory receptors/ molecules; (vi) inhibit the activity and proliferation of cancer stem cells; (vii) inhibit tumor growth; and (viii) promote survival (Figures 1-2). Further, the anti-cancer activity of Clostridium butyricum MIYAIRI 588 (CBM588) can be further increased by treating cancer patients with probiotic Lactobacillus rhamnosus  (1.0×103 CFU/ml). Thus, a pharmacological formulation encompassing probiotics “Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus” may be used to inhibit the progression of advanced  cancers and promote disease-free survival (Figure 3)

Figure 1. Mechanistic insights into how  Clostridium butyricum MIYAIRI 588 (CBM588) increases the expression of tumor/metastatic suppressors, such as  BTG2, SMARCA4,  p53, TAp73/p63, INK4a, p19ARF and others.

Figure 2.Clostridium butyricum MIYAIRI 588 (CBM588) functions as a tumor/metastatic suppressors agent not only in advanced cancers but also in mutant-p53 expressing human tumors

Figure 3. A pharmacological formulation encompassing probiotics “Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus” may attenuate the progression of advanced  cancers through induction of tumor/metastatic suppressors, such as BTG2, SMARCA4, p53, TAp73/p63, INK4a, p19ARF and others

Details of the Research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Amount: $1, 500#

Undisclosed mechanistic information: How does Clostridium butyricum MIYAIRI 588 (CBM588) increase the expression of tumor/metastatic suppressors BTG2, SMARCA4, and others?

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

#Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as  BTG2, SMARCA4, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 30/January/2019, `7.38 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, Kindly drop us a line at admin@genomediscovery.org

Comments are closed.